Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLMD 
Galmed Pharmaceuticals Ltd (GLMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: GLMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.63% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.15M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.28 | 52 Weeks Range 0.74 - 3.61 | Updated Date 12/1/2025 |
52 Weeks Range 0.74 - 3.61 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.61 |
Earnings Date
Report Date 2025-11-26 | When - | Estimate -0.79 | Actual -0.33 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.9% | Return on Equity (TTM) -46.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -7451071 | Price to Sales(TTM) - |
Enterprise Value -7451071 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.32 | Shares Outstanding 5479231 | Shares Floating 5403563 |
Shares Outstanding 5479231 | Shares Floating 5403563 | ||
Percent Insiders 0.92 | Percent Institutions 1.04 |
Upturn AI SWOT
Galmed Pharmaceuticals Ltd
Company Overview
History and Background
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for liver diseases. Founded in 2000 in Israel, it has focused primarily on developing Aramchol for NASH and other liver conditions. The company has undergone various clinical trials to evaluate Aramchol's efficacy and safety.
Core Business Areas
- Drug Development: Galmed focuses on the research, development, and commercialization of novel therapies for liver diseases, primarily non-alcoholic steatohepatitis (NASH).
Leadership and Structure
The company's leadership includes a CEO, CFO, and a board of directors. The organizational structure is typical of a clinical-stage biopharmaceutical company, emphasizing research and development.
Top Products and Market Share
Key Offerings
- Aramchol: Aramchol is Galmed's lead product candidate, an SCD1 modulator being developed for the treatment of NASH. Although Aramchol's trials did not meet endpoints, it remains a key asset. Competitors include Madrigal Pharmaceuticals (MDGL) with resmetirom and Viking Therapeutics (VKTX) with VK2809, both in NASH treatment. There is currently no market share data available as the drug is not currently approved.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the NASH treatment market, is highly competitive and rapidly evolving. Several companies are developing therapies to address this growing medical need.
Positioning
Galmed aims to position itself in the NASH treatment market with Aramchol, focusing on its potential as a treatment option. The company faces strong competition from larger pharmaceutical companies.
Total Addressable Market (TAM)
The NASH market is projected to be worth billions of dollars. Galmed's success depends on their ability to gain regulatory approval and capture market share in this competitive landscape.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidate (Aramchol)
- Experienced management team
Weaknesses
- Clinical trial failures
- Limited financial resources
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Potential for breakthrough therapy designation
- Expansion into other liver disease indications
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Financial constraints
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- AKRO
Competitive Landscape
Galmed faces significant competition from larger, well-funded pharmaceutical companies with more advanced or diverse pipelines. Its success hinges on differentiating Aramchol from other NASH therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been minimal due to its status as a clinical-stage company with no marketed products. Growth has been solely in developing Aramchol.
Future Projections: Future growth depends on the successful development and commercialization of Aramchol or other pipeline assets. Analyst estimates vary widely due to the inherent risk in drug development.
Recent Initiatives: Recent initiatives likely include pursuing alternative development strategies for Aramchol or exploring new indications.
Summary
Galmed Pharmaceuticals is a high-risk, high-reward clinical-stage biotech company with a focus on liver diseases. Clinical trial setbacks have challenged its growth trajectory, and the company needs to improve its financials. Success depends on strategic partnerships and expanding the application of Aramchol.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Financial news outlets
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. The pharmaceutical industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galmed Pharmaceuticals Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-03-13 | Co-Founder, President, CEO & Chairman Mr. Allen Baharaff | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://galmedpharma.com |
Full time employees 3 | Website https://galmedpharma.com | ||
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.